Latest News

ImmBio today announced a partnership with CPI, Darlington, to develop a heat-stabilised formulation for PnuBioVax, ImmBio’s multi-antigen vaccine candidate against Pneumococcal diseases. This will eliminate the requirement for a costly and complex cold chain, helping to reduce the cost of the vaccine and increase accessibility in LMICs (Low and Middle Income Countries) where cold chains may be lacking. https://www.uk-cpi.com/news/cpi-partners-with-immunobiology-ltd-to-manufacture-heat-stabilised-pneumococcal-vaccine-formulation... Read more

Following the strategic licensing deal with CNBG, the largest Pharmaceutical Vaccine company in China, earlier this year, ImmunoBiology Ltd (“ImmBio”) has announced that it is searching for additional strategic partners to develop and commercialise its universal pneumococcal vaccine, PnuBioVax™. AEC Partners, a leading life-sciences advisory firm head quartered in Paris, has been appointed to support this initiative which is at Phase 2 clinical stage of development. ... Read more

Cambridge, UK - 18 March 2019 - ImmunoBiology Ltd (ImmBio), a vaccine R&D company based at Babraham Research Campus near Cambridge UK, has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product) a subsidiary company under CNBG. This partnership will enable ImmBio and LIBP to co-develop ImmBio’s proprietary PnuBioVax vaccine against pneumococcal disease and launch the pneumococcal vaccine in the Greater China area upon completion of successful clinical studies. This Sino-UK high-tech partnership deal has been possible as a result of the long-lasting successful relation between the companies and strong pre-clinical and Phase I clinical data obtained by ImmBio in the development of the pneumococcal vaccine to date. In addition to the multi-million milestone and royalty payment agreement, the licensing agreement provides a strategic alliance for ImmBio, allowing access to the partner’s strong technical ability and manufacturing capacity that could facilitate the development and commercialisation of the vaccine in the Rest of the World. ... Read more

ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, reports positive results from the First-in-Human study of its novel vaccine, PnuBioVax™, against the bacterial pathogen Streptococcus pneumoniae (NCT02572635). PnuBioVax was found to be safe and well tolerated, and capable of producing antibody responses against key S. pneumoniae antigens broadly conserved across strains. The data was presented today at the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Glasgow, UK “... Read more

Cambridge, UK, 10 December 2015 — ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, today announces that it has initiated enrolment for a First-in-Human study of its novel vaccine (“PnuBioVax™”) against the bacterial pathogen Streptococcus pneumoniae.... Read more

UK government-backed Biomedical Catalyst has awarded ImmBio £0.2 million ($0.3 million) to support pre-clinical development of PnuBioVax™... Read more